Skip to main content
OpenTrials
Completed

NCT Number: NCT00099853

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to pioglitazone in people with type 2 diabetes not at target blood glucose levels on either pioglitazone or rosiglitazone alone.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Novartis Pharmaceuticals

East Hanover, New Jersey, 07936, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Blood glucose criteria must be met
  • Previously responded, as defined by the protocol, to treatment with pioglitazone or rosiglitazone
  • Body mass index (BMI) in the range 22-45

Exclusion criteria

  • Type 1 diabetes
  • Pregnancy or lactation
  • Evidence of serious cardiovascular complications
  • Evidence of serious diabetic complications
  • Laboratory value abnormalities as defined by the protocol
  • Known sensitivity to pioglitazone
  • Other protocol-defined exclusion criteria may apply

Treatment and study plan

Vildagliptin

Drug

Vildagliptin 50 mg tablets

Other names: LAF237, Galvus

pioglitazone

Drug

pioglitazone 45 mg qd

Placebo

Drug

Vildagliptin matching placebo

Primary outcomes

  1. Change from baseline in HbA1c after 24 weeks

Secondary outcomes

  1. Change from baseline in fasting plasma glucose at 24 weeks

  2. Patients with endpoint HbA1c <7% after 24 weeks

  3. Patients with reduction in HbA1c >/= to 0.7% after 24 weeks

  4. Adverse event profile after 24 weeks of treatment

  5. Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs low baseline HbA1c

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Important dates

Study start
2004
Primary completion
2008
Study completion
2008
First posted
Dec 22, 2004
Registry last updated
Dec 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.